Literature DB >> 12771943

Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity.

Andrew Tutt1, Frances Connor, David Bertwistle, Peter Kerr, John Peacock, Gill Ross, Alan Ashworth.   

Abstract

Carriers of mutations in the BRCA2 gene are at a highly elevated risk of breast and other cancers. The BRCA2 gene encodes a very large protein thought to play a role in DNA repair. To examine the effect of mutation of BRCA2 on sensitivity to ionizing radiation, we used a previously described mouse model system (Brca2(Tr)) in which the Brca2 open reading frame is truncated. Mouse embryo fibroblasts carrying this mutation have a proliferative defect, which we show here can be substantially rescued by genetic ablation of p53. Proliferating Brca2(Tr/Tr)/p53(-/-) cells, like Brca2(Tr/Tr) cells, show genomic instability. We used the clonogenic survival assay, which depends on the ability of cells to proliferate, to examine the cell cycle dependence of radiation sensitivity of Brca2(Tr/Tr)/p53(-/-) compared to p53(-/-) and wild-type cells. This showed that the Brca2 mutation had little effect on cells irradiated in quiescence but sensitized proliferating cells to ionizing radiation on a p53(-/-) background. These results suggest that the major role of Brca2 in mediating cell survival after irradiation is in the S and G(2) phases of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771943     DOI: 10.1038/sj.onc.1206522

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

Review 1.  Links between mutant p53 and genomic instability.

Authors:  Walter Hanel; Ute M Moll
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

Review 2.  Genetic and epigenetic features in radiation sensitivity Part I: cell signalling in radiation response.

Authors:  Michel H Bourguignon; Pablo A Gisone; Maria R Perez; Severino Michelin; Diana Dubner; Marina Di Giorgio; Edgardo D Carosella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02       Impact factor: 9.236

3.  The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers.

Authors:  Danny Vesprini; Steven A Narod; John Trachtenberg; Juanita Crook; Farid Jalali; John Preiner; Srikala Sridhar; Robert G Bristow
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

4.  Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.

Authors:  Fiona A Dungey; Keith W Caldecott; Anthony J Chalmers
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

5.  Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.

Authors:  Keiko Yata; Janette Lloyd; Sarah Maslen; Jean-Yves Bleuyard; Mark Skehel; Stephen J Smerdon; Fumiko Esashi
Journal:  Mol Cell       Date:  2012-02-10       Impact factor: 17.970

6.  A Focal Adhesion-Related Gene Signature Predicts Prognosis in Glioma and Correlates With Radiation Response and Immune Microenvironment.

Authors:  Haonan Li; Guohui Wang; Wenyan Wang; Jie Pan; Huandi Zhou; Xuetao Han; Linlin Su; Zhenghui Ma; Liubing Hou; Xiaoying Xue
Journal:  Front Oncol       Date:  2021-09-22       Impact factor: 6.244

7.  Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers.

Authors:  Mihriban Karaayvaz-Yildirim; Rebecca E Silberman; Adam Langenbucher; Srinivas Vinod Saladi; Kenneth N Ross; Elena Zarcaro; Andrea Desmond; Murat Yildirim; Varunika Vivekanandan; Hiranmayi Ravichandran; Ravindra Mylavagnanam; Michelle C Specht; Sridhar Ramaswamy; Michael Lawrence; Angelika Amon; Leif W Ellisen
Journal:  Sci Adv       Date:  2020-01-29       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.